Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Brain-derived neurotrophic factor (BDNF) activates the receptor tropomyosin-related kinase B (TrkB) with high potency and specificity, promoting neuronal survival, differentiation, and synaptic function. Correlations between altered BDNF expression and/or function and mechanism(s) underlying numerous neurodegenerative conditions, including Alzheimer disease and traumatic brain injury, suggest that TrkB agonists might have therapeutic potential. Using in silico screening with a BDNF loop-domain pharmacophore, followed by low-throughput in vitro screening in mouse fetal hippocampal neurons, we have efficiently identified small molecules with nanomolar neurotrophic activity specific to TrkB versus other Trk family members. Neurotrophic activity was dependent on TrkB and its downstream targets, although compound-induced signaling activation kinetics differed from those triggered by BDNF. A selected prototype compound demonstrated binding specificity to the extracellular domain of TrkB. In in vitro models of neurodegenerative disease, it prevented neuronal degeneration with efficacy equal to that of BDNF, and when administered in vivo, it caused hippocampal and striatal TrkB activation in mice and improved motor learning after traumatic brain injury in rats. These studies demonstrate the utility of loop modeling in drug discovery and reveal what we believe to be the first reported small molecules derived from a targeted BDNF domain that specifically activate TrkB.We propose that these compounds constitute a novel group of tools for the study of TrkB signaling and may provide leads for developing new therapeutic agents for neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LM22A-4 was designed to mimic the loop II domain of BDNF and proven to be a partial agonist.”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Massa et al. 2010
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In vitro work showed that LM22A-4 has neuroprotective properties (Massa et al. 2010).”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Massa et al. 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
Trk Receptors: Roles in Neuronal Signal Transduction
Huang, E. J., & Reichardt, L. F. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161629 · Cited by 2,537
Neurotrophins and their receptors: A convergence point for many signalling pathways
Chao, M. V. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1078 · Cited by 2,298
Neurotrophin signal transduction in the nervous system
Kaplan, D. R., & Miller, F. D. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00092-1 · Cited by 1,944
Virtual screening of chemical libraries
Shoichet, B. K. (2004) · Nature · doi:10.1038/nature03197 · Cited by 1,425
Ageing and neuronal vulnerability
Mattson, M. P., & Magnus, T. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1886 · Cited by 957
Sairanen, M., Lucas, G., Ernfors, P., Castrén, M., & Castrén, E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3741-04.2005 · Cited by 763
TrkB Regulates Hippocampal Neurogenesis and Governs Sensitivity to Antidepressive Treatment
Li, Y., Luikart, B. W., Birnbaum, S., Chen, J., Kwon, C.-H., Kernie, S. G., Bassel-Duby, R., & Parada, L. F. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.023 · Cited by 634
Poduslo, J. F., & Curran, G. L. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(95)00250-v · Cited by 614
Research works printed but not linked: 1
- Conte, 2008, Restor Neurol Neurosci., 26, 45
Cited by
Items 201–300 of 403
Zhu, C., Rodda, A. E., Truong, V. X., Shi, Y., Zhou, K., Haynes, J. M., Wang, B. H., Cook, W. D., & Forsythe, J. S. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b00084 · Cited by 28
TrkB agonists prevent postischemic emergence of refractory neonatal seizures in mice
Kipnis, P. A., Sullivan, B. J., Carter, B. M., & Kadam, S. D. (2020) · JCI Insight · doi:10.1172/jci.insight.136007 · Cited by 27
“In conjunction with the proposed binding of LM to TrkB (14), and the observation that LM intervention was efficacious, our data suggested that the presence and subsequent binding of LM to TrkB also prevented the cascade of endogenous postischemic BDNF/TrkB signaling, similar to the TrkB antagonist ANA12.”
BackgroundMethodInfluentialChiu, Y., Lin, T., Chang, K., Lin, W., Hsieh‐Li, H. M., Su, M., Chen, C., Sun, Y., & Lee‐Chen, G. (2022) · Aging · doi:10.18632/aging.204306 · Cited by 27
“LM22A-4 has a poor BBB penetration ability [58].”
BackgroundChou, P. C., Shunmugavel, A., Sayed, H. E., Desouki, M. M., Nguyen, S. A., Khan, M., Singh, I., & Bilgen, M. (2011) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.22574 · Cited by 26
“007] and during the entire time of exposure [Day: F(3,63) 1⁄4 20.”
BackgroundInfluentialSelf-citationRenno, W. M., Khan, K. M., & Benov, L. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.029 · Cited by 28
“Also, these molecules caused hippocampal and striatal Trk-B activation in mice and improved motor learning after traumatic brain injury in rats (Massa et al., 2010).”
BackgroundDelivery of neurotrophic factors in the treatment of age-related chronic neurodegenerative diseases
Padmakumar, S., Taha, M. S., Kadakia, E., Bleier, B. S., & Amiji, M. M. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1727443 · Cited by 26
Joshi, R., & Salton, S. R. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.932497 · Cited by 27
Stimulating myelin restoration with BDNF: a promising therapeutic approach for Alzheimer's disease
Zota, I., Chanoumidou, K., Gravanis, A., & Charalampopoulos, I. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1422130 · Cited by 25
“The compound demonstrated efficacy in preventing neuronal degeneration in vitro comparable to BDNF (Massa et al., 2010).”
ResultPPARβ/δ and γ in a Rat Model of Parkinson's Disease: Possible Involvement in PD Symptoms
Falcone, R., Florio, T. M., Giacomo, E. D., Benedetti, E., Cristiano, L., Antonosante, A., Fidoamore, A., Massimi, M., Alecci, M., Ippoliti, R., et al. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25041 · Cited by 26
“…OF CELLULAR BIOCHEMISTRY PPARb/d AND g IN A RAT MODEL OF PARKINSONS DISEASE 851 JOURNAL OF CELLULAR BIOCHEMISTRY852 PPARb/d AND g IN A RAT MODEL OF PARKINSONS DISEASE and release, thereby promoting the growth of neurons via the TrkB pathways [Massa et al., 2010; Yoshii and Constantine, 2010].”
BackgroundClass 3 semaphorins as a therapeutic target
Goshima, Y., Sasaki, Y., Yamashita, N., & Nakamura, F. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.710201 · Cited by 25
“For example, despite no available crystal structure for BDNF--TrkB complex, Cazorla et al. derived a threedimensional (3D) model of BDNF--TrkB complex from the existing crystal structures of the neurotorophin-4/5 (NT-4/5)-TrkB complex and the BDNF/NT-3 dimer [30].”
BackgroundInfluentialUliassi, E., Gandini, A., Perone, R. C., & Bolognesi, M. L. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0038 · Cited by 24
Developing Insulin and BDNF Mimetics for Diabetes Therapy
Chan, C. B., Ahuja, P., & Ye, K. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191010160643 · Cited by 24
Activation of endothelial TrkB receptors induces relaxation of resistance arteries
Totoson, P., Pédard, M., Marie, C., & Demougeot, C. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.02.005 · Cited by 25
Mocchetti, I., Bachis, A., Campbell, L. A., & Avdoshina, V. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9488-y · Cited by 23
“More recently, a non-peptidergic compound derived from the loop II region of BDNF has shown to activate TrkB in vitro and in vivo (Massa et al. 2010).”
Unsicker, K. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1585-y · Cited by 26
“Moreover, small molecule BDNF mimetics that bind to TrkB and trigger downstream signaling have been shown to be useful therapeutic drugs in initial studies (Massa et al. 2010; Jang et al. 2010; Monteggia 2011).”
BackgroundBernard‐Gauthier, V., Boudjemeline, M., Rosa‐Neto, P., Thiel, A., & Schirrmacher, R. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.10.012 · Cited by 23
A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis
Collongues, N., Becker, G., Jolivel, V., Ayme‐Dietrich, E., Seze, J. D., Binamé, F., Patte‐Mensah, C., Monassier, L., & Mensah‐Nyagan, A. G. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00363-7 · Cited by 25
Targeted stabilization of Munc18‐1 function via pharmacological chaperones
Abramov, D., Guiberson, N. G. L., Daab, A., Na, Y., Petsko, G. A., Sharma, M., & Burré, J. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012354 · Cited by 24
“Several studies have successfully identified small molecule mimetics for BDNF from in silico studies that are able to either specifically activate or antagonize TrkB, the BDNF receptor, and are also active in vivo (Massa et al , 2010; Cazorla et al , 2011) .”
The Relationship Between Plasma BDNF and Pain in Older Adults With Knee Osteoarthritis
Sorkpor, S. K., Galle, K., Teixeira, A. L., Colpo, G. D., Ahn, B., Jackson, N. A., Miao, H., & Ahn, H. B. (2021) · Biological Research For Nursing · doi:10.1177/10998004211012479 · Cited by 22
“…characterized by changes in the central pain processing network that result in disproportionate amplification of central neuronal response to either normal or sub-threshold sensory input, leading to hypersensitivity to pain, (Meeus & Nijs, 2007; Woolf, 2004) has often been proposed as a possible”
BackgroundOstrova, I. V., Голубева, Н. В., Kuzovlev, A. N., & Golubev, A. M. (2019) · General Reanimatology · doi:10.15360/1813-9779-2019-1-70-86 · Cited by 31
“Another BDNF mimetic, LM22A-4, a TrkB receptor agonist, prevented neuronal degeneration, enhanced neurogenesis and improved functional recovery in studies on brain ischemia models in vitro and in vivo [63, 68].”
BackgroundInfluentialIshimoto, T., Yamashita, R., Matsumoto, R., Matsumoto, S., Matsuo, Y., Nakao, S., Masuo, Y., Suzuki, M., & Kato, Y. (2024) · npj Science of Food · doi:10.1038/s41538-024-00250-5 · Cited by 22
“ERGO and S-methyl ERGO concentrations at weeks 4, 8, and 12 were signi fi cantly higher than those at week 0 in the ERGO-treated group, whereas serum concentrations of S-methyl ERGO and hercynine were much lower than those of ERGO in both the ERGO-treated and placebo groups (Supplementary Fig.”
InfluentialRocha, L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.009 · Cited by 24
Glial cell line-derived neurotrophic factor family ligands and their therapeutic potential
Sidorova, Y. A., & Saarma, M. (2016) · Molecular Biology · doi:10.1134/s0026893316040105 · Cited by 22
Optical Activation of TrkB Signaling
Huang, P., Liu, A., Song, Y., Hope, J. M., Cui, B., & Duan, L. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.05.002 · Cited by 21
Зайнуллина, Л. Ф., Vakhitova, Y. V., Lusta, A. Y., Гудашева, Т. А., & Середенин, С. Б. (2021) · Scientific Reports · doi:10.1038/s41598-021-87435-0 · Cited by 21
From understanding synaptic plasticity to the development of cognitive enhancers
Cheung, Z. H., & Ip, N. Y. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001537 · Cited by 22
“Interestingly, a recent study reported the identification of a small molecule BDNF mimetic that reduces neurotoxin-induced neuronal loss in vitro, in addition to restoring motor learning following traumatic brain injury (Massa et al. 2010).”
BackgroundAdams, I. T., Yang, T., Longo, F. M., & Katz, D. M. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.044685 · Cited by 20
“To independently test and further confirm the necessity of TrkB activation in the biological activity of PTX-BD4-3, we examined the effects of a function-blocking antibody directed against the extracellular domain (ECD) of TrkB (anti-TrkB) that is known to inhibit BDNF activity (Massa et al., 2010).”
BackgroundMethodInfluentialSelf-citationBaazaoui, N., & Iqbal, K. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170075 · Cited by 21
“Similar to this neuroprotective effect of P021, a previous study reported that BDNF agonist compounds (LM 22A-1 to 4) derived from the BDNF loop domain prevent neurodegeneration in vitro [17].”
Yu, H. J., Kim, Y. L., Kim, M. J., Park, J. M., Park, S. Y., Park, S. N., & Yang, D. W. (2022) · Brain Research · doi:10.1016/j.brainres.2022.147900 · Cited by 19
Javed, S., Chang, Y.-T., Cho, Y., Lee, Y., Chang, H., Haque, M., Lin, Y. C., & Huang, W. (2023) · eLife · doi:10.7554/elife.90333 · Cited by 20
“We systematically treated mice with LM22A-4, a potential small molecule BDNF loop domain mimetic ( Massa et al., 2010 ).”
MethodTremendous Fidelity of Vitamin D3 in Age-related Neurological Disorders
Skv, M., Abraham, S. M., Eshwari, O., Golla, K., Jhelum, P., Maity, S., & Komal, P. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-03989-w · Cited by 20
“In ischemic stroke model, VD supplementation increased the protein expression of BDNF with an enhancement in tropomyosin receptor kinase B (TrkB) receptor protein expression [180, 181].”
A novel dimeric dipeptide mimetic of the BDNF selectively activates the MAPK-Erk signaling pathway
Гудашева, Т. А., Тарасюк, А. В., Sazonova, N. M., Povarnina, P. Y., Антипова, Т. А., & Середенин, С. Б. (2017) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672917050027 · Cited by 20
Zafer, D., Aycan, N., Özaydın, B., Kemanli, P., Ferrazzano, P. A., Levine, J. E., & Cengiz, P. (2019) · Neuroendocrinology · doi:10.1159/000499661 · Cited by 20
Jeon, M., Moon, G. J., Kim, S., Choi, M., Oh, Y., Kim, D. W., Kim, H., Lee, K. J., Choe, Y., Ha, C. M., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14882 · Cited by 19
“Increased BDNF expression induces neuroprotective effects, such as anti‐neurodegeneration and improved cognitive ability in models of AD in vivo and in vitro (Jeon et al., 2015; Jeronimo‐Santos et al., 2015; Massa et al., 2010; Nagahara et al., 2009).”
BackgroundBDNF Outperforms TrkB Agonist 7,8,3′-THF in Preserving the Auditory Nerve in Deafened Guinea Pigs
Vink, H. A., van Dorp, W. C., Thomeer, H. G. X. M., Versnel, H., & Ramekers, D. (2020) · Brain Sciences · doi:10.3390/brainsci10110787 · Cited by 20
Zborowski, V. A., Heck, S. O., Marques, L. S., Bastos, N. K., & Nogueira, C. W. (2021) · Physiology & Behavior · doi:10.1016/j.physbeh.2021.113346 · Cited by 20
Lucaci, A. G., Notaras, M. J., Pond, S. L. K., & Colak, D. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02021-w · Cited by 21
“BDNF has correspondingly been the primary target, or an ancillary factor, of many novel therapeutics including small molecule mimetics [23, 24] and existing drugs (e.”
BackgroundCharou, D., Rogdakis, T., Latorrata, A., Valcárcel, M., Papadogiannis, V., Athanasiou, C., Tsengenes, A., Papadopoulou, M. A., Lypitkas, D., Lavigne, M. D., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03818-w · Cited by 18
Ohnishi, T., Sakamoto, K., Asami-Odaka, A., Nakamura, K., Shimizu, A., Ito, T., Asami, T., Ohtaki, T., & Inooka, H. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.186 · Cited by 18
“In recent years, small molecules, such as the LM22A series, have been reported as TrkB agonists [5].”
BackgroundKang, M., Chong, K. Y., Hartwich, T. M. P., Bi, F., Witham, A. K., Patrick, D. A., Morrisson, M. J., Cady, S. L., Cerchia, A. P., Kelk, D. A., et al. (2020) · Oncogenesis · doi:10.1038/s41389-020-0243-y · Cited by 18
Ji, E., Kim, Y.-M., Ko, Y. J., & Baek, S. (2020) · Journal of Exercise Rehabilitation · doi:10.12965/jer.2040618.309 · Cited by 18
“…development, differentiation, and survival through the receptor tyrosine kinase B (TrkB), and BDNF is secreted by activity-dependent modulators (Massa et al., 2010). https://doi.org/10.12965/jer.2040618.309 Original Article Journal of Exercise Rehabilitation…”
BackgroundInfluentialTraub, S., Stahl, H. F., Rosenbrock, H., Simon, E., Florin, L., Hospach, L., Hörer, S., & Heilker, R. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.240184 · Cited by 19
“For pathway inhibition experiments, 10 ml/well of 20 mM K252a, 100 mM PD98059, 50 mM LY294002, or 100 mM U73122 diluted in stimulation buffer were added to the cellular supernatant before agonist addition.”
BackgroundInfluentialChronic partial TrkB activation reduces seizures and mortality in a mouse model of Dravet syndrome
Gu, F., Parada, I., Yang, T., Longo, F. M., & Prince, D. A. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022726119 · Cited by 17
Self-citationPeptidergic Drugs For the Treatment of Traumatic Brain Injury
Alvarez, X. A., Figueroa, J., & Muresanu, D. F. (2013) · Future Neurology · doi:10.2217/fnl.12.95 · Cited by 19
“Further support for the protective effects of BDNF in TBI arises from pharmacological studies demonstrating that: BDNF mimetics activate TrkB receptors and improve learning after TBI in rats;([46]) human mesenchymal stem cells seem to improve TBI functional recovery by increasing the secretion of BDNF and other neurot…”
BackgroundCulture of Rodent Cortical, Hippocampal, and Striatal Neurons
Facci, L., & Skaper, S. D. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7571-6_3 · Cited by 17
Characterising lipoteichoic acid as an in vitro model of acute neuroinflammation
Howe, A.-M., Cosgrave, A., Murchú, M. Ó., Britchfield, C., Mulvagh, A., Fernández-Pérez, I., Dykstra, M., Jones, A. C., & Costello, D. A. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106619 · Cited by 18
Fan, C.-H., Lin, C.-W., Huang, H.-J., Lee‐Chen, G., Sun, Y., Lin, W., Chen, C., Chang, K., Su, M., & Hsieh‐Li, H. M. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05602-z · Cited by 19
Гудашева, Т. А., Povarnina, P. Y., Антипова, Т. А., & Середенин, С. Б. (2014) · Neuroscience & Medicine · doi:10.4236/nm.2014.52013 · Cited by 17
Łuczkowski, M. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.03.001 · Cited by 18
Huang, H., Yan, P., Sun, T., Mo, X., Yin, J., Li, P., Zhu, Y., Rong, S., Yang, W. Q., Chen, X., et al. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/4572893 · Cited by 17
Toward Neurotrophin-Based Therapeutics
Monteggia, L. M. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10111677 · Cited by 18
“Recent work has suggested that the use of small molecules to activate TrkB may be a viable tool for the study of this receptor signaling pathway as well as a potential therapeutic strategy for a number of brain disorders (4, 5).”
BackgroundThirty years of BDNF study in central myelination: From biology to therapy
Xiao, J. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15968 · Cited by 17
“It prevents neural cell death, an effect similar to BDNF (Massa et al., 2010).”
BackgroundResultInfluentialD-cycloserine improves synaptic transmission in an animal mode of Rett syndrome
Na, E. S., Jesús‐Cortés, H. D., Martínez-Rivera, A., Kabir, Z. D., Wang, J., Ramesh, V., Onder, Y., Rajadhyaksha, A. M., Monteggia, L. M., & Pieper, A. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183026 · Cited by 17
Lazaldin, M. A. M., Iezhitsa, I. N., Agarwal, R., Agarwal, P., & Ismail, N. M. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.346546 · Cited by 17
“TrkB receptors are activated by binding to the cognate ligand BDNF and undergo dimerisation with the unliganded monomeric form, which is thought to be in equilibrium with its phosphorylated dimeric state (Massa et al., 2010).”
BackgroundC3-Symmetric Ligands in Drug Design: When the Target Controls the Aesthetics of the Drug
Antonijevic, M., Rochais, C., & Dallemagne, P. (2023) · Molecules · doi:10.3390/molecules28020679 · Cited by 17
“The main idea in its development was the generation of a pharmacophore hypothesis based on the sub region b on the BDNF loop II, [19] which includes Ser94, Lys95 and Lys96 residues (Figure 7A).”
BackgroundInfluentialAntiepileptogenic repair of excitatory and inhibitory synaptic connectivity after neocortical trauma
Prince, D. A., Gu, F., & Parada, I. (2016) · Progress in brain research · doi:10.1016/bs.pbr.2016.03.013 · Cited by 16
Hannan, M. A., Haque, M. N., Dash, R., Alam, M., & Moon, I. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-55364-8 · Cited by 16
Sun, T., Chen, S., Huang, H., Li, T., Yang, W. Q., & Liu, L. (2017) · Journal of Chromatography B · doi:10.1016/j.jchromb.2017.07.001 · Cited by 16
Mitra, S., Munni, Y. A., Dash, R., Sultana, A., & Moon, I. S. (2022) · Phytotherapy Research · doi:10.1002/ptr.7466 · Cited by 16
Culture of Rodent Cortical and Hippocampal Neurons
Facci, L., & Skaper, S. D. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-536-7_5 · Cited by 15
Ambjørn, M., Dubreuil, V., Miozzo, F., Nigon, F., Møller, B. K., Issazadeh‐Navikas, S., Berg, J., Lees, M. J., & Sap, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065371 · Cited by 15
“Another recent strategy is the development of BDNF mimetics specifically enhancing TrkB signaling, which have showed promising results in rodent neurodegenerative models [29].”
BackgroundSánchez-González, A., Mendieta, L., Palafox-Sánchez, V., Candalija, A., Luna, F., Aguilera, J., & Limón, I. D. (2014) · Neuroscience Research · doi:10.1016/j.neures.2014.04.008 · Cited by 14
Shariati, A., Kumar, V., Yang, T., Chakraborty, C., Barres, B. A., Longo, F. M., & Liao, Y. J. (2018) · Current Eye Research · doi:10.1080/02713683.2018.1508726 · Cited by 15
“However, in human cementoblast-like (HCEM) cell line, use of an MEKERK inhibitor (U0126) attenuates pro-survival molecules such as ERK and Akt and TrkB activation.(66) Therefore, it is likely that LM22A-4 might have pro-survival effect by MAPK pathways.”
BackgroundSelf-citationZhao, S., Li, X., Lu, P., Li, X., Ming-fei, S., & Wang, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.646723 · Cited by 14
Small-Molecule Trk Agonists: Where Do We Go from Here?
Thompson, T. S., Sefiani, A., & Burgess, K. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02365 · Cited by 13
Medeiros, D., Ayala-Baylon, K., Egido‐Betancourt, H. X., Miller, E. C., Chapleau, C. A., Robinson, H., Phillips, M. L., Yang, T., Longo, F. M., Li, W., et al. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050612 · Cited by 13
“Because of its partial agonism at TrkB receptors (Massa et al., 2010), LM22A-4 had no effect on spine density in pyramidal neurons from male WT mice ( P >0.9999, ANOVA-Bonferroni ’ s; n =12 control WT neurons/11 slices versus n =13 LM22A-4 WT neurons/9 slices), where typical BDNF levels outcompete…”
InfluentialSelf-citationAntonijevic, M., Charou, D., Ramos, I., Valcárcel, M., Gravanis, A., Villacé, P., Callizot, N., Since, M., Dallemagne, P., Charalampopoulos, I., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115111 · Cited by 13
Wang, Z.-D., Yao, G., Wang, W., Wang, W., Wang, S., & Song, S. (2017) · Steroids · doi:10.1016/j.steroids.2017.06.013 · Cited by 13
Ye, S., Xie, D., Zhou, P., Gao, H., Zhang, M., Chen, D., Qin, Y.-P., Lei, X., Li, X., Liu, J., et al. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/5514175 · Cited by 14
Neurotrophins: The therapeutic potential and concept of minipeptides
Гомазков, О. А. (2012) · Neurochemical Journal · doi:10.1134/s1819712412030075 · Cited by 13
The Neurotrophic-Like Effect of Carvacrol: Perspective for Axonal and Synaptic Regeneration
Sisti, F., dos Santos, N. A. G., do Amaral, L., & dos Santos, A. C. (2021) · Neurotoxicity Research · doi:10.1007/s12640-021-00341-1 · Cited by 14
Neurotrophin Strategies for Neuroprotection: Are They Sufficient?
Steiner, J. P., & Nath, A. (2014) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9533-5 · Cited by 13
“…Longo identified numerous structures from in silico screening of the loop II region of BDNF and by low throughput screening of hippocampal neurons (Massa et al. 2010) These four prototypic compounds were neuroprotective Table 1 (continued) Class System(s) References carbamazepam rats in vivo…”
BackgroundInfluentialTacke, C., DiStefano, P. S., Lindsay, R. M., Metzdorf, K., Zagrebelsky, M., & Körte, M. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.945348 · Cited by 12
Therapeutic Strategies for Huntington’s Disease
Mrzljak, L., & Muñoz-Sanjuán, I. (2013) · Current topics in behavioral neurosciences · doi:10.1007/7854_2013_250 · Cited by 13
“…dimerization, phosphorylation, and signaling via ERK and pI3 K pathways, calling into question whether the reported effects truly reflect a direct modulation of this signaling pathway (Fletcher and Hughes 2009; Jiang et al. 2013; Marongiu et al. 2013; Massa et al. 2010; O’Leary and Hughes 2003).”
BackgroundProtective effects of LM22A-4 on injured spinal cord nerves.
Yu, G., & Wang, W. (2015) · Europe PMC (PubMed Central) · Cited by 17
Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging
Schirrmacher, R., Bailey, J. J., Mossine, A. V., Scott, P. J. H., Kaiser, L., Bartenstein, P., Lindner, S., Kaplan, D. R., Kostikov, A. P., Fricker, G., et al. (2019) · Pharmaceuticals · doi:10.3390/ph12010007 · Cited by 12
Modulation of Neurotrophin Signaling by Monoclonal Antibodies
Rosenthal, A., & Lin, J. C. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-45106-5_19 · Cited by 12
Kingwell, K. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3190 · Cited by 12
Palantzas, A., & Anagnostouli, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178217 · Cited by 11
“Instead, alternative strategies using TrkB agonists (7,8-DHF), which mimic BDNF signaling [75,81,82] and small-molecules like curcumin, resveratrol, and J-147 that boost BDNF and exert anti-inflammatory and antioxidant effects, are being explored [75].”
Can Brain-derived Neurotrophic Factor (BDNF) Mimetics be a Way Out for Neurodegenerative Diseases?
Korkmaz, O. T. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230127142414 · Cited by 12
Upscaling of hiPS Cell–Derived Neurons for High-Throughput Screening
Traub, S., Stahl, H. F., Rosenbrock, H., Simon, E., & Heilker, R. (2016) · SLAS DISCOVERY · doi:10.1177/1087057116678161 · Cited by 12
Neurotrophin Signaling and Alzheimer’s Disease Neurodegeneration − Focus on BDNF/TrkB Signaling
Wong, J. (2013) · InTech eBooks · doi:10.5772/53364 · Cited by 11
“Moreover, in cell culture and animal models, functioning of the BDNF signaling pathway has been repeatedly demonstrated to be critical for neuronal differentiation, survival, plasticity, and cognition [3, 11, 13, 15-21].”
BackgroundЛогвинов, И. О., Антипова, Т. А., Гудашева, Т. А., Тарасюк, А. В., Антипов, П. И., & Середенин, С. Б. (2013) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-013-2149-6 · Cited by 11
Jmaeff, S., Sidorova, Y. A., Lippiatt, H., Barcelona, P. F., Nedev, H. N., Saragovi, L. M., Hancock, M. A., Saarma, M., & Saragovi, H. U. (2020) · Molecular Pharmacology · doi:10.1124/mol.119.118950 · Cited by 10
“Comparable to the functional cross-talk between GFRa1 and RET described here, there are reported agonists of Trk receptors (Maliartchouk et al., 2000; Zaccaro et al., 2005; Massa et al., 2010) whose function can be regulated by p75NTR coreceptors.”
BackgroundIdentification of TrkB Binders from Complex Matrices Using a Magnetic Drug Screening Nanoplatform
Arituluk, Z. C., Horne, J., Adhikari, B., Steltzner, J., Mansur, S., Ahirwar, P., Velu, S. E., Gray, N. E., Ciesla, L. M., & Bao, Y. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00552 · Cited by 10
Nafian, F., Rasaee, M. J., Yazdani, S., Daftarian, N., Soheili, Z., & Azad, B. K. D. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28036 · Cited by 12
Effect of Tie-2 conditional deletion of BDNF on atherosclerosis in the ApoE null mutant mouse
Norata, G. D., Venu, V. K. P., Callegari, E., Paloschi, V., & Catapano, A. L. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.02.014 · Cited by 9
“Furthermore, a series of pharmacological approaches aimed at modulating the BDNF/TrkB axis is under investigation not only for neurological disorders [30] but also for vascular disorders associated to dementia and as well as BDNF-mediated angiogenesis [31,32].”
BackgroundElia, A., Parodi‐Rullán, R. M., Vázquez‐Torres, R., Carey, A. M., Zhao, H., Javadov, S. A., & Fossati, S. (2026) · Advanced Science · doi:10.1002/advs.202511924 · Cited by 11
“To confirm the protective effect of TrkB activation in our model, we stimulated human cardiomyocytes with the selective TrkB receptor agonist, LM22A-4 [ 35 ] (Figure 6C,D ), in the presence or absence of A β 40 oligomers [ 36 ].”
Sazonova, N. M., Тарасюк, А. В., Шумский, А. Н., Povarnina, P. Y., Круглов, С. В., Антипова, Т. А., Гудашева, Т. А., & Середенин, С. Б. (2018) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-018-1896-0 · Cited by 9
Moffat, J. J., Sakhai, S. A., Hoisington, Z. W., Ehinger, Y., & Ron, D. (2023) · Psychopharmacology · doi:10.1007/s00213-022-06305-3 · Cited by 9
Age-Dependency of Neurite Outgrowth in Postnatal Mouse Cochlear Spiral Ganglion Explants
Frick, C., Fink, S., Schmidbauer, D., Rousset, F., Eickhoff, H., Tropitzsch, A. S., Kramer, B., Senn, P., Glueckert, R., Rask‐Andersen, H., et al. (2020) · Brain Sciences · doi:10.3390/brainsci10090580 · Cited by 9
Neurotrophin peptidomimetics for the treatment of neurodegenerative diseases
Madhubala, D., Mahato, R., Khan, M. R., Bala, A., & Mukherjee, A. K. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104156 · Cited by 8
Zhang, W., Miao, Y., Xing, Z., Li, H., Liu, H., & Li, Z. (2012) · Muscle & Nerve · doi:10.1002/mus.23689 · Cited by 8
“BDNF has high potency for promoting neuronal survival, differentiation, and synaptic function.(30) The presence of BDNF is necessary for the maintenance of DRG neurons in vivo.”
BackgroundDevelopment of Precision Small-Molecule Proneurotrophic Therapies for Neurodegenerative Diseases
Janssens, J., Lu, D., Ni, B., Chadwick, W., Siddiqui, S., Azmi, A. S., Etienne, H., Jushaj, A., van Gastel, J., Martin, B., et al. (2016) · Vitamins and hormones · doi:10.1016/bs.vh.2016.10.006 · Cited by 9
Islam, T., Majumder, M., Kalita, B., Bhattacharjee, A., Mukhopadhyay, R., & Mukherjee, A. K. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15153 · Cited by 8
“Noteworthy, the TrkA acts as the receptor for mammalian NGF, whereas TrkB preferentially binds with brain-derived neurotrophic factors and NT-4/5, and TrkC is the preferred receptor for neurotrophin-3 (Massa et al., 2010).”
BackgroundDevelopment of Pleiotropic TrkB and 5-HT4 Receptor Ligands as Neuroprotective Agents
Antonijevic, M., Charou, D., Davis, A., Curel, T., Valcárcel, M., Ramos, I., Villacé, P., Claeysen, S., Dallemagne, P., Gravanis, A., et al. (2024) · Molecules · doi:10.3390/molecules29020515 · Cited by 8
“One such small molecule is LM22A-4 [17]; however, this molecule does not possess desirable physicochemical pro fi le, since it is quite hydrophilic (chromatographic hydrophobicity index (CHI) at pH = 4 = 13.8) 7.4 is [18].”
BackgroundInfluentialGu, F., Parada, I., Yang, T., Longo, F. M., & Prince, D. A. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhz254 · Cited by 8
“BD is a derivative of the TrkB-specific partial agonist parent compound LM22A-4 (Massa et al. 2010) and has higher blood–brain barrier permeability, longer serum half-life, and better absorption following oral administration compared to the parent compound.”
BackgroundSelf-citationHo, C., Luchetta, J., Nash, B., Festa, L. K., Johnson, J. A., Saçan, A., Jackson, J. G., Sanz-Clemente, A., Brandimarti, R., & Meucci, O. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.2213-24.2025 · Cited by 7
Jeyabalan, J. B., Palathoti, N., Dhanasekaran, M., Sivasamy, R., Ponnusankar, S., Dhanabal, S. P., Sankar, V., & Justin, A. (2023) · Neurological Sciences · doi:10.1007/s10072-023-06684-1 · Cited by 8
“The study also concluded that the compound triggered neuronal cell differentiation and survival [83].”
BackgroundZhu, Y., Moksha, L., Salowe, R., Vrathasha, V., Pham, K., Aibo, M.-A. I., Lee, R., Halimitabrizi, M., Rosa, I. D., & O’Brien, J. M. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118319 · Cited by 9
“For instance, small molecule BDNF mimetics have been shown to activate TrkB signaling and prevent neuronal degeneration in preclinical models [99].”
Metadata
- Authors
- Massa, S. M., Yang, T., Xie, Y., Shi, J., Bilgen, M., Joyce, J. N., Nehama, D., Rajadas, J., & Longo, F. M.
- Affiliations
- University of California, San Francisco (US)
- Stanford University (US)
- University of North Carolina at Chapel Hill (US)
- Medical University of South Carolina (US)
- Banner Sun Health Research Institute (US)
- Corresponding author
- Longo, Frank M.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2010-05-03
- Volume
- 120
- Issue
- 5
- Pages
- 1774-1785
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2860903
- OpenAlex
- W2055583081
- Cited by
- 406
- References
- 64
- Citations by year
- 2026: 6 · 2025: 22 · 2024: 18 · 2023: 25 · 2022: 22 · 2021: 21 · 2020: 42 · 2019: 22 · 2018: 18 · 2017: 26 · 2016: 23 · 2015: 21 · 2014: 40 · 2013: 41 · 2012: 32
- FWCI
- 12.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Defense (DAMD170310532)
- U.S. Department of Veterans Affairs
- Alzheimer's Association
- Koret Foundation
- Jean Perkins Foundation
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Keywords
- BDNF mimetic, TrkB signaling, brain-derived neurotrophic factor, small molecule agonists, neurotrophic activity, neurodegeneration, traumatic brain injury, Alzheimer's disease, pharmacophore modeling, loop domains, hippocampal neurons, motor learning, neurodegenerative disease therapeutics
- MeSH terms
- Animals, Hippocampus, Kinetics, Male, Mice, Inbred C57BL, Models, Biological, Neurons, Phosphorylation, Protein Binding, Signal Transduction, Rats, Sprague-Dawley, Brain-Derived Neurotrophic Factor, Neurodegenerative Diseases, Receptor, trkB, NIH 3T3 Cells, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.